Crown Bioscience
About Crown Bioscience
Crown Bioscience is a company based in Santa Clara (United States) founded in 2006 was acquired by Aidikang Medical Laboratory Center in November 2025. Crown Bioscience has raised $85.87 million across 4 funding rounds from investors including Orbimed, JSR Corporation and European Union. The company has 18 employees as of December 31, 2022. Crown Bioscience has completed 3 acquisitions, including OcellO, PRECOS and PreClinOmics. Crown Bioscience offers products and services including PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services. Crown Bioscience operates in a competitive market with competitors including Evotec, Alloy Therapeutics, Domainex, NIH and Viva Biotech, among others.
- Headquarter Santa Clara, United States
- Employees 18 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Crown Bioscience, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Crown Bioscience
Crown Bioscience offers a comprehensive portfolio of products and services, including PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services.
Preclinical models for testing oncology drugs in humanized mice.
Cell-derived xenograft models for cancer research applications.
Models for immuno-oncology studies using immune-competent mice.
3D cell cultures for evaluating drug responses in oncology.
Tools for genomics and proteomics data in drug development.
Funding Insights of Crown Bioscience
Crown Bioscience has successfully raised a total of $85.87M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $159.68 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Crown Bioscience
Crown Bioscience has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, JSR Corporation and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Crown Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Crown Bioscience
Crown Bioscience has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include OcellO, PRECOS and PreClinOmics.
Investment portfolio details for Crown Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
3D screening services for drug discovery are offered.
|
Locked | Locked | 2011 | Locked | |
|
Preclinical oncology services with xenograft and metastatic models are provided.
|
Locked | Locked | 2010 | Locked | |
|
Contract research organization (CRO) with expertise in Metabolic, Renal and Cardiovascular disease
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Crown Bioscience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Crown Bioscience
Detailed financials for Crown Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crown Bioscience Comparisons
Peer comparison for Crown Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Crown Bioscience
Crown Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Alloy Therapeutics, Domainex, NIH and Viva Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Crown Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crown Bioscience
Complete news archive for Crown Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crown Bioscience
Crown Bioscience was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Crown Bioscience is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Armin Spura is the current CEO of Crown Bioscience.
Crown Bioscience is a funded company, having raised a total of $85.87M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Crown Bioscience is 18.
Crown Bioscience develops drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases). The companys proprietary platform includes HuPrime that is a patient-derived xenograft (PDX) models which can be used for efficacy testing. It also offers oncology services, such as oncology databases, ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical models (PDX, Humanized and Murine efficacyPD) for CAR-T Therapy Evaluation (immuno-oncology) etc., CrownBio also has a variety of rodent and mouse models for the development of drugs for CVMD. The company also offers products, such as antibodies for in vivo and in-vitro studies, tissues for CVMD research, tumor samples for Oncology RD, cytokines and growth factors for use in basic and preclinical research, recombinant proteins and cell lines for biological studies, immune checkpoint antibodies and tumor tissue microarrays. CrownBio has strategic partnerships with Xstrahl, a designer, and manufacturer of X-Ray solutions for radiation biology research and Horizon Discovery, a provider of advanced research tools and services for the development of personalized medicines. CrownBio acquired PreClinOmics, an in vivo preclinical company specializing in CVMD and renal disease research. The company has spun-off CBT pharmacueticals, an emerging life science oncology company.
Crown Bioscience offers PDX Models, CDX Models, Syngeneic Models, Organoids, and Bioinformatics Services.
Crown Bioscience has made 3 acquisitions, including OcellO, PRECOS, and PreClinOmics.
Crown Bioscience has 10 investors. Key investors include Orbimed, JSR Corporation, European Union, Qiming Venture Partners, and CDIB Capital Group.